Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
54
BBH Quote, Financials, Valuation and Earnings
Last price:
$191.88
Seasonality move
:
3.66%
Day range:
$191.95 - $193.00
52-week range:
$135.34 - $198.08
Dividend yield:
0.5%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.7K
Avg. volume:
9.3K
1-year change:
20.88%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBH
VanEck Biotech ETF
|
$192.42 | -- | -- | -- | $0.96 | 0.5% | -- |
|
AGNG
Global X Aging Population ETF
|
$36.50 | -- | -- | -- | $0.14 | 0.79% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$47.20 | -- | -- | -- | $0.03 | 0.07% | -- |
|
HEAL
Global X HealthTech ETF
|
$29.76 | -- | -- | -- | $0.02 | 0.08% | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
$26.78 | -- | -- | -- | $0.16 | 1.15% | -- |
|
PPH
VanEck Pharmaceutical ETF
|
$104.43 | -- | -- | -- | $0.39 | 1.85% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBH
VanEck Biotech ETF
|
-- | 0.599 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.484 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 1.886 | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | 1.781 | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | 0.936 | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | 0.233 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | -- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- | -- |
VanEck Biotech ETF vs. Competitors
-
Which has Higher Returns BBH or AGNG?
Global X Aging Population ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About BBH or AGNG?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than Global X Aging Population ETF, analysts believe VanEck Biotech ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is BBH or AGNG More Risky?
VanEck Biotech ETF has a beta of 0.791, which suggesting that the stock is 20.873% less volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.722%.
-
Which is a Better Dividend Stock BBH or AGNG?
VanEck Biotech ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 0.5%. Global X Aging Population ETF offers a yield of 0.79% to investors and pays a quarterly dividend of $0.14 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or AGNG?
VanEck Biotech ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns BBH or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About BBH or GNOM?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe VanEck Biotech ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is BBH or GNOM More Risky?
VanEck Biotech ETF has a beta of 0.791, which suggesting that the stock is 20.873% less volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.286, suggesting its more volatile than the S&P 500 by 28.563%.
-
Which is a Better Dividend Stock BBH or GNOM?
VanEck Biotech ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 0.5%. Global X Genomics & Biotechnology ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.03 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or GNOM?
VanEck Biotech ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns BBH or HEAL?
Global X HealthTech ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat Global X HealthTech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- HEALGlobal X HealthTech ETF-- -- -- -
What do Analysts Say About BBH or HEAL?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X HealthTech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than Global X HealthTech ETF, analysts believe VanEck Biotech ETF is more attractive than Global X HealthTech ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 HEALGlobal X HealthTech ETF0 0 0 -
Is BBH or HEAL More Risky?
VanEck Biotech ETF has a beta of 0.791, which suggesting that the stock is 20.873% less volatile than S&P 500. In comparison Global X HealthTech ETF has a beta of 1.219, suggesting its more volatile than the S&P 500 by 21.903%.
-
Which is a Better Dividend Stock BBH or HEAL?
VanEck Biotech ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 0.5%. Global X HealthTech ETF offers a yield of 0.08% to investors and pays a quarterly dividend of $0.02 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. Global X HealthTech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or HEAL?
VanEck Biotech ETF quarterly revenues are --, which are smaller than Global X HealthTech ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than Global X HealthTech ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while Global X HealthTech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for Global X HealthTech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- HEALGlobal X HealthTech ETF-- -- -- --
-
Which has Higher Returns BBH or IDNA?
iShares Genomics Immunology and Healthcare ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat iShares Genomics Immunology and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -
What do Analysts Say About BBH or IDNA?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Genomics Immunology and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than iShares Genomics Immunology and Healthcare ETF, analysts believe VanEck Biotech ETF is more attractive than iShares Genomics Immunology and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 -
Is BBH or IDNA More Risky?
VanEck Biotech ETF has a beta of 0.791, which suggesting that the stock is 20.873% less volatile than S&P 500. In comparison iShares Genomics Immunology and Healthcare ETF has a beta of 1.066, suggesting its more volatile than the S&P 500 by 6.579%.
-
Which is a Better Dividend Stock BBH or IDNA?
VanEck Biotech ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 0.5%. iShares Genomics Immunology and Healthcare ETF offers a yield of 1.15% to investors and pays a quarterly dividend of $0.16 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. iShares Genomics Immunology and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or IDNA?
VanEck Biotech ETF quarterly revenues are --, which are smaller than iShares Genomics Immunology and Healthcare ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than iShares Genomics Immunology and Healthcare ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while iShares Genomics Immunology and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for iShares Genomics Immunology and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- --
-
Which has Higher Returns BBH or PPH?
VanEck Pharmaceutical ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat VanEck Pharmaceutical ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- PPHVanEck Pharmaceutical ETF-- -- -- -
What do Analysts Say About BBH or PPH?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand VanEck Pharmaceutical ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than VanEck Pharmaceutical ETF, analysts believe VanEck Biotech ETF is more attractive than VanEck Pharmaceutical ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 PPHVanEck Pharmaceutical ETF0 0 0 -
Is BBH or PPH More Risky?
VanEck Biotech ETF has a beta of 0.791, which suggesting that the stock is 20.873% less volatile than S&P 500. In comparison VanEck Pharmaceutical ETF has a beta of 0.549, suggesting its less volatile than the S&P 500 by 45.102%.
-
Which is a Better Dividend Stock BBH or PPH?
VanEck Biotech ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 0.5%. VanEck Pharmaceutical ETF offers a yield of 1.85% to investors and pays a quarterly dividend of $0.39 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. VanEck Pharmaceutical ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or PPH?
VanEck Biotech ETF quarterly revenues are --, which are smaller than VanEck Pharmaceutical ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than VanEck Pharmaceutical ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while VanEck Pharmaceutical ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for VanEck Pharmaceutical ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- PPHVanEck Pharmaceutical ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
